Oral Magnesium Supplementation and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial
The objective of the study was to evaluate the efficacy of oral magnesium supplementation in the improvement of metabolic syndrome (MetS) and its components. This is a randomized double-blind, placebo-controlled clinical trial that enrolled 198 individuals with MetS and hypomagnesemia who were randomly allocated to receive either 30 mL of magnesium chloride 5% solution, equivalent to 382 mg of elemental magnesium (n = 100), or placebo solution (n = 98), daily for 16 weeks. Serum magnesium levels <1.8 mg/dL defined hypomagnesemia. At final conditions, a total of 48 (48%) and 76 (77.5%) individuals had MetS in the...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Magnesium and Drugs Commonly Used in Chronic Kidney Disease
Publication date: May 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 3Author(s): Jeffrey H. William, Katelyn Richards, John DanzigerAs with other electrolytes, magnesium homeostasis depends on the balance between gastrointestinal absorption and kidney excretion. Certain drugs used commonly in patients with CKD can decrease gastrointestinal ingestion and kidney reclamation, and potentially cause hypomagnesemia. Other magnesium-containing drugs such as laxatives and cathartics can induce hypermagnesemia, particularly in those with impaired glomerular filtration and magnesium excretion. In this review, we wi...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Magnesium and Progression of Chronic Kidney Disease: Benefits Beyond Cardiovascular Protection?
Publication date: May 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 3Author(s): Yusuke Sakaguchi, Takayuki Hamano, Yoshitaka IsakaExperimental and clinical studies have demonstrated that magnesium deficiency leads to hypertension, insulin resistance, and endothelial dysfunction, and is associated with an increased risk of cardiovascular events. Given that cardiovascular disease and CKD share similar risk factors, the low magnesium status may also contribute to CKD progression. In fact, lower serum magnesium levels and lower dietary magnesium intake are associated with an increased risk of incident CKD an...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Magnesium as a Calcification Inhibitor
Publication date: May 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 3Author(s): Lucie Hénaut, Ziad A. MassyVascular calcification (VC) is associated with elevated cardiovascular mortality rates in patients with CKD. Recent clinical studies of patients with advanced CKD have observed an association between low serum magnesium (Mg) levels on one hand and elevated VC and cardiovascular mortality on the other. These findings have stimulated interest in understanding Mg's impact on CKD in general and the associated VC in particular. In vitro and preclinical in vivo data indicate that Mg has the potential t...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Magnesium Balance in Chronic and End-Stage Kidney Disease
This article explores the effects of CKD and end-stage kidney disease on magnesium balance. In CKD, there is decreased glomerular filtration of magnesium. Decreased tubular reabsorption can compensate to a degree, but once CKD stage 4 is reached there is a tendency toward hypermagnesemia. In dialysis, magnesium balance is dependent on the constituents of the dialysate that the blood is exposed to. The concentration of dialysate magnesium is just one of the factors that need to be considered. During transplantation, there are particular effects of immunosuppressants that can affect the magnesium balance and need to be consi...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
